Scott Jackson

Scott Jackson

Director/Board Member at MACROGENICS, INC.

Net worth: 217 010 $ as of 31/05/2026

61 year
Health Technology
Consumer Services
Health Services

Profile

Scott T.
Jackson
is currently an Independent Director at MacroGenics, Inc. since 2017, an Independent Director at Spero Therapeutics, Inc. since 2020, and a Director at Philabundance.
Former roles include Chief Executive Officer & Director at Jazz Pharmaceuticals Therapeutics, Inc. from 2008 to 2016, Chairman at Mural Oncology Plc from 2023 to 2025, Independent Director at GlycoMimetics, Inc. from 2018 to 2025, Principal at Centocor, Inc. from 2002 to 2004, Principal at ImClone LLC, Principal at Eli Lilly & Co. from 1988 to 1993, Principal at Smithkline Beecham Plc, Vice President-Marketing at YM BioSciences, Inc. from 2004 to 2007, Vice President-Marketing at YM BioSciences USA, Inc. from 2004 to 2006, and Trustee-Eastern Pennsylvania Chapter at Blood Cancer United, Inc. from 2013 to 2019.
Education includes an MBA from the University of Notre Dame and undergraduate studies at Philadelphia College of Pharmacy.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
01/04/2026 55,000 ( 0.09% ) 155 650 $ 31/05/2026
19/05/2026 14,750 ( 0.02% ) 61 360 $ 31/05/2026

Scott Jackson active positions

CompaniesPositionStart
MACROGENICS, INC. Director/Board Member 25/01/2017
SPERO THERAPEUTICS, INC. Director/Board Member 16/04/2020
Director/Board Member -

Former positions of Scott Jackson

CompaniesPositionEnd
Director/Board Member 21/02/2025
Corporate Officer/Principal 01/06/2019
CELATOR PHARMACEUTICALS INC Chief Executive Officer 12/07/2016
Sales & Marketing 01/05/2007
See the detail of Scott Jackson's experience

Training of Scott Jackson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

55

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Services

Health Technology

Commercial Services

Health Technology

Consumer Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!